company EVO - SteadyBase

steadybase-$ company EVO

account_id none on file

legal_name Evotec SE

ticker EVO

cik 1412558

domain evotec.com

linkedin_company_url https://www.linkedin.com/company/evotec

entry_point_account_id none on file

exchange Nasdaq

sector Health Care

hq Hamburg, Germany

irhttps://www.evotec.com/ir-news/investor-relations

sector index/company/sector/health-care/

calls 2 filings 60 executives 3 family 0

why_nownone on file

calls

In terms of headcount reduction, what you see if you think about the elements that I described, first of all, we have closure of the site in Cologne and exit of other headcount that has taken place over the course of the first quarter. So think February, March predominantly. Then we also have our new kind of attrition, net attrition run rate that we exit the year, exit 2024 on a lower flight level. So part of that is already within our run rate going into the year. And then we have some additional extra in the first quarter, as we see some level of net attrition outflow.

May 6, 2025 / receipt, needs a key / Paul, other | earnings call 2025-05-06 | transcript 6741124a-e36c-4149-853b-97f79d3e6d1d | chars 22821-23398 | segment 23

Going forward, we are focusing our R&D spend on further developing our proprietary platform technology. Investments into own, unpartnered assets are limited to scientific proof points. This is reflected in a reduction of the flight level of R&D spending in 2025.

Apr 17, 2025 / receipt, needs a key / Christian, CEO | earnings call 2025-04-17 | transcript f893439b-2a6e-4a3c-bac6-d5db374ae1b1 | chars 26797-27059 | segment 28

filings

Accelerating cost-out plans & further productivity improvement